Article

Multidrug resistant tuberculous meningitis in the United States, 1993-2005

Drexel University College of Medicine, Department of Medicine, Division of Infectious Diseases & HIV Medicine, 245 North 15th Street, Mailstop 461, 6308 New College Building, Philadelphia, PA 19102-1192, USA.
The Journal of infection (Impact Factor: 4.02). 07/2011; 63(3):240-2. DOI: 10.1016/j.jinf.2011.07.005
Source: PubMed
0 Followers
 · 
128 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Drug-resistant tuberculosis, including drug-resistant tuberculous meningitis, is an emerging health problem in many countries. An association with Beijing strains and drug resistance-related mutations, such as mutations in katG and rpoB genes, has been found. The pathology, clinical features and neuroimaging characteristics of drug-resistant tuberculous meningitis are similar to drug-responsive tuberculous meningitis. Detection of mycobacteria in cerebrospinal fluid (CSF) by conventional methods (smear examination or culture) is often difficult. Nucleic acid amplification assays are better methods owing to their rapidity and high sensitivity. The Xpert(®) MTB/RIF assay (Cepheid, CA, USA) is a fully-automated test that has also been found to be effective for CSF samples. Treatment of multidrug-resistant tuberculous meningitis depends on the drug susceptibility pattern of the isolate and/or the previous treatment history of the patient. Second-line drugs with good penetration of the CSF should be preferred. Isoniazid monoresistant disease requires addition of another drug with better CSF penetration. Drug-resistant tuberculous meningitis is associated with a high mortality. HIV infected patients with drug-resistant tuberculous meningitis have severe clinical manifestations with exceptionally high mortality. Prevention of tuberculosis is the key to reduce drug-resistant tuberculous meningitis.
    Expert Review of Anticancer Therapy 06/2013; 11(6):605-21. DOI:10.1586/eri.13.39 · 3.06 Impact Factor